[1] Dhaliwal D, Shepherd TG. Molecular and cellular mechanisms controlling integrin-mediated cell adhesion and tumor progression in ovarian cancer metastasis: a review[J]. Clin Exp Metastasis, 2022, 39:291-301. doi: 10.1007/s10585-021-10136-5. [2] Zhang Y, Tan CY, Spjut RW, et al. Specialized metabolites of the United States lichen Niebla homalea and their antiproliferative activities[J]. Phytochemistry, 2020, 180:112521-1125.doi: 10.1016/j.phytochem. [3] Chardin L, Leary A. Immunotherapy in ovarian cancer: thinking beyond PD-1/PD-L1[J]. Front Oncol, 2021, 11:795547-795556. doi: 10.3389/fonc.2021.795547. [4] Dumitru A, Dobrica EC, Croitoru A, et al. Focus on PD-1/PD-L1 as a therapeutic target in ovarian cancer[J]. Int J Mol Sci, 2022, 23:12067-12080. doi: 10.3390/ijms232012067. [5] Sun TX, Li M, Zhang ZH, et al. Usnic acid suppresses cervical cancer cell proliferation by inhibiting PD-L1 expression and enhancing T-lymphocyte tumor-killing activity[J]. Phytother Res, 2021, 35:3916-3935. doi: 10.1002/ptr.7103. [6] 王晓妮, 郭涛, 罗启云, 等. 松萝酸对增生性瘢痕成纤维细胞生物学行为及JNK/MAPK信号通路的影响[J]. 吉林大学学报(医学版), 2023, 49:1445-1451. doi: 10.13481/j.1671-587X.20230606. [7] 郝凯华, 韩涛,胡鹏斌. 松萝酸抑制小鼠H22肿瘤生长及作用机制研究[J]. 中国药师, 2 016, 19:29-32. doi: 10.3969/j.issn.1008-049X.2016.01.008 [8] 黄洁, 李润博, 郭建新, 等. DDX5和DDX17在卵巢癌组织中的表达及对人卵巢癌细胞系SKOV3增殖和耐药的影响[J] 基础医学与临床202343:1247-1253. doi: 10.16352/j.issn.1001-6325.2023.08.1247. [9] Cansaran-Duman D, Tanman Ü, Yangin S, et al. The comparison of miRNAs that respond to anti-breast cancer drugs and usnic acid for the treatment of breast cancer[J]. Cytotechnology, 2020, 72:855-872. doi: 10.1007/s10616-020-00430-7. [10] Wu W, Gou H, Dong J, et al. Usnic acid inhibits proliferation and migration through ATM mediated DNA damage response in RKO colorectal cancer cell[J]. Curr Pharm Biotechnol, 2021, 22:1129-1138.doi: 10.2174/1389201021666201002155955. [11] Özben RŞ, Cansaran-Duman D. The expression profiles of apoptosis-related genes induced usnic acid in SK-BR-3 breast cancer cell[J]. Hum Exp Toxicol, 2020, 39:1497-1506. doi: 10.1177/0960327120930257. [12] Tang Q, Chen Y, Li X, et al. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers[J]. Front Immunol, 2022, 13:964442-964460.doi: 10.3389/fimmu.2022.964442. [13] Zeng Y, Li B, Liang Y, et al. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment[J]. FASEB J, 2019, 33:6596-6608.doi: 10.1096/fj.201802067RR. [14] Xiao X, Zeng S, Li Y, et al. Aspirin suppressed PD-L1 expression through suppressing KAT5 and subsequently inhibited PD-1 and PD-L1 signaling to attenuate OC development[J]. J Oncol, 2022, 1:4664651-4664663. doi: 10.1155/2022/4664651. |